Elizabeth could have saved herself many of these charges by telling investors she was pivoting to using 3rd party testing devices, reducing the number of tests, and transitioning to a business model involving venous blood drawing as a service with lower costs and better branding. Instead, she decided to continue to lie to investors even though she knew her tech didn’t work as she represented.